Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

MAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern Medicine

May 12, 2021 • 7:57 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

After the Multidisciplinary Association for Psychedelic Studies (MAPS) published promising results from a clinical trial using MDMA to treat post-traumatic stress disorder (PTSD), the psychedelic therapy sector has received extra attention. 

According to The New York Times, MAPS could receive FDA approval by 2023 and we are favorable on the data that is associated with the study. This comes after the Imperial College London’s study of the use of psilocybin to treat depression was published by The New England Journal of Medicine.

Peter Thiel is a high-profile investor that is involved with several companies that are focused on developing FDA approved psychedelic therapies. One of the companies, Atai Life Sciences is expected to go public in the near future and is an opportunity that we are excited about. 

One of the reasons we are excited about companies that are focused on developing these types of treatments is due to the size of the markets. Currently, there are several companies that are researching a variety of ways to treat mental health with alternative and psychedelic therapies and we expect positive clinical trial data to support the growth of the industry. 

The current treatment approach for people who are taking medication for depression and PTSD is expensive and puts a burden on the entire health-care system. If companies like MAPS and Atai continues to report positive clinical trial data, these biotech firms could be a major beneficiary of a substantial shift in the healthcare industry.  

According to the National Institute of Health (NIH), 51.5 million people in the US were living with a mental illness in 2019. We believe the COVID pandemic has put additional stress on people and expect the number of people who live with a mental illness to increase as a result. 

From a regulatory standpoint, we are seeing significant improvements in the US. Currently, Denver and Oregon have decriminalized psychedelics like psilocybin and we are favorable on this trend. If the legalization movement follows what we saw in the cannabis industry, we could be in the first inning of a long-term growth cycle and will continue to closely follow how the industry advances.

If you are interested in learning more about the psychedelic therapy sector, please send an email to support@mushroomstocks.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link